




Instance: composition-en-41b3735a6e59fac8a0512a47fdc116bd
InstanceOf: CompositionUvEpi
Title: "Composition for lupkynis Package Leaflet"
Description:  "Composition for lupkynis Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp043229dc0e0f21b924ddb8c3894e484a)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - lupkynis"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Lupkynis is and what it is used for </li>
<li>What you need to know before you take Lupkynis </li>
<li>How to take Lupkynis </li>
<li>Possible side effects </li>
<li>How to store Lupkynis </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What lupkynis is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What lupkynis is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Lupkynis contains the active substance voclosporin. It is used for the treatment of adults from 18 years 
of age with lupus nephritis (inflammation of the kidney caused by lupus). </p>
<p>The active ingredient in Lupkynis is one of a group of medicines known as calcineurin inhibitors that 
can be used to control your body s immune response (immunosuppressants). In lupus, the immune 
system (the body s natural defences) mistakenly attacks parts of your own body, including the kidneys 
(lupus nephritis). By reducing the response of the immune system, the medicine reduces inflammation 
of your kidneys and lessens symptoms such as swelling of the legs, ankles or feet, high blood pressure, 
tiredness, as well as improving your kidney function. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take lupkynis"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take lupkynis"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Lupkynis 
- If you are allergic to voclosporin or any of the other ingredients of this medicine (listed in 
section 6). 
- If you are taking other medicines such as ketoconazole tablets (used to treat Cushing s 
syndrome when the body produces an excess of cortisol), itraconazole or clarithromycin (used 
to treat certain fungal and bacterial infections). </p>
<p>Warnings and precautions 
Talk to your doctor or pharmacist before taking Lupkynis if any of the following applies to you:</p>
<ul>
<li>if your kidney disease gets worse, your dose of this medicine may need to be changed. Your 
doctor will regularly check how well your kidneys are working. </li>
<li>if you have risk factors for pure red cell aplasia (PRCA)   a rare disorder in which the bone 
marrow does not make enough red blood cells. Such risk factors are a former infection with 
parvovirus B19 or other treatments in the past that may cause PRCA. </li>
<li>if you suffer from or develop high blood pressure. Your doctor will check your blood pressure 
every two weeks for the first month and then regularly. He/she may give you a medicine to 
lower your blood pressure or tell you to stop taking this medicine. </li>
<li>This medicine can increase the risk of conditions of the nervous system, such as headache, 
shaking, changes in vision, seizures, confusion or weakness in one or more limbs. If you 
experience any of these new symptoms or worsening of existing symptoms, your doctor may 
consider stopping or lowering the dose of this medicine (see section 4). </li>
<li>if you are planning to have a vaccination or have had a vaccination within the last 30 days. This 
medicine may affect the response to vaccination, and vaccination during treatment with this 
medicine may be less effective. </li>
<li>if you have previously experienced sudden life-threatening allergic reactions (anaphylactic 
reactions) to soya or peanut, do not take this medicine. </li>
</ul>
<p>This medicine can increase the potassium levels in your blood, which may be serious and require 
treatment. Your doctor will check your potassium levels periodically during treatment. </p>
<p>This medicine has not been studied in patients with severe liver problems and is therefore not 
recommended in these patients. </p>
<p>This medicine may influence the electrical activity of your heart (QT prolongation). This can result in 
serious heart rhythm disorder. Early symptoms are dizziness and fainting.  </p>
<p>Sunlight and UV light 
This medicine can increase the risk of developing certain types of cancer, particularly of the skin. You 
should avoid or limit your exposure to sunlight and UV light by wearing appropriate protective 
clothing and frequently applying sunscreen with a high protection factor. </p>
<p>Infections 
This medicine can increase your risk of developing infections, some of which may be serious or even 
fatal. Contact your doctor if you have any signs of infection, such as fever, chills or sore throat. Your 
doctor will decide whether you need to stop taking this medicine (see section 4). </p>
<p>Children and adolescents 
Do not take this medicine if you are under the age of 18 years because it has not been studied in this 
age group. </p>
<p>Elderly 
This medicine is not recommended if you are over the age of 75 years because it has not been studied 
in this age group. </p>
<p>Other medicines and Lupkynis 
Tell your doctor or pharmacist if you are taking or have recently taken or are planning to take any 
other medicines. </p>
<p>In particular, tell your doctor if you take:</p>
<ul>
<li>Medicines used to treat fungal infection such as itraconazole and fluconazole. </li>
<li>Medicines used to treat Cushing s syndrome (when the body produces an excess of cortisol), 
such as ketoconazole tablets. </li>
<li>Medicines used to treat high blood pressure or heart problems such as digoxin, diltiazem and 
verapamil. </li>
<li>Medicines to prevent the formation of blood clots such as dabigatran etexilate. </li>
<li>Medicines used to treat epilepsy such as carbamazepine and phenobarbital. </li>
<li>Herbal preparations containing St. John s Wort, used to treat mild depression. </li>
<li>Medicines for the relief of symptoms associated with seasonal allergic rhinitis such as 
fexofenadine. </li>
<li>Antibiotic medicines used to treat bacterial infections such as rifampicin, clarithromycin and 
erythromycin. </li>
<li>Medicines that lower cholesterol such as simvastatin, atorvastatin, rosuvastatin and pravastatin. </li>
<li>Medicines used to treat HIV infections, such as the antiretroviral efavirenz. </li>
</ul>
<p>Lupkynis with food and drink 
This medicine can be taken with or without food. Avoid eating grapefruit and drinking grapefruit juice 
during treatment with this medicine, since these can affect how the medicine works. </p>
<p>Pregnancy, breast-feeding and fertility 
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor for advice before taking this medicine. </p>
<p>This medicine is not recommended during pregnancy and in women of childbearing potential not 
using contraception. </p>
<p>Tell your doctor if you are breast-feeding. It is not known if the medicine can pass into breast milk and 
affect your baby. Your doctor will discuss with you whether to stop treatment with this medicine while 
you are breast-feeding, or to stop breast-feeding. </p>
<p>There are no data on the effect of this medicine on human fertility. </p>
<p>Driving and using machines 
Lupkynis is not expected to have any effect on your ability to drive and use machines. </p>
<p>Lupkynis contains alcohol 
This medicine contains 21.6 mg of alcohol (ethanol) in each capsule. Therefore, a dose of 3 capsules 
of Lupkynis contains 64.8 mg ethanol, which is equivalent to less than 2 mL beer or 1 mL wine. This 
small amount of alcohol in this medicine will not have any noticeable effects. </p>
<p>Lupkynis contains sorbitol 
This medicine contains 28.7 mg of sorbitol in each capsule. </p>
<p>Lupkynis may contain soya lecithin<br />
This medicine may contain trace amounts of soya lecithin. If you experience anaphylactic reactions to 
soya or peanut, you must not use this medicine. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take lupkynis"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take lupkynis"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist 
if you are not sure. </p>
<p>The recommended dose of Lupkynis is three capsules twice daily, taken by mouth. </p>
<p>The capsules must be swallowed whole and can be taken with or without food. </p>
<p>Take the daily doses at around the same time each day, at least 8 hours apart and ideally as close to hours apart as possible (for example, at 8:00 am in the morning and 8:00 pm in the evening). </p>
<p>This medicine should be used in combination with another immunosuppressant medicine, 
mycophenolate mofetil. </p>
<p>If you take more Lupkynis than you should 
If you have accidentally taken too many capsules, contact your doctor or nearest hospital emergency 
department immediately. Symptoms of overdose may include a fast heartbeat and tremors 
(uncontrolled shaking or trembling in one or more parts of the body). </p>
<p>If you forget to take Lupkynis 
If a dose is missed, take it as soon as possible and within 4 hours of missing the dose. If more than 4 
hours have passed since the time you normally take the medicine, just skip that dose and take the next 
regular dose at the usual time. Do not take a double dose to make up for a forgotten dose. </p>
<p>If you stop taking Lupkynis 
Do not stop your treatment unless your doctor tells you to do so. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The 
following side effects may happen with this medicine: </p>
<p>Serious side effects </p>
<p>If any of these occur, seek immediate medical advice as your doctor may advise you to stop taking this 
medicine or reduce the dose. </p>
<p>Very common (may affect more than 1 in 10 people) 
- Symptoms of infection (such as fever, body aches, feeling tired, coughing or sneezing, nausea, 
vomiting or diarrhoea) </p>
<p>Common (may affect up to 1 in 10 people) 
- Newly developing symptoms of nerve or brain problems, such as seizures </p>
<p>Other side effects </p>
<p>Very common (may affect more than 1 in 10 people) 
- Upper chest infection 
- Reduction in red blood cells which can make the skin pale and cause weakness or breathlessness 
(anaemia) 
- Headache 
- Increased blood pressure 
- Cough 
- Diarrhoea 
- Pain in the abdomen (belly) 
- Changes in your kidney function which could reduce the amount of urine you produce and may 
cause new or worsening swelling in your legs or feet </p>
<p>Common (may affect up to 1 in 10 people) 
- Infections, that can either be bacterial such as urinary tract infections or viral such as shingles 
- Inflammation of the stomach and intestines 
- Flu 
- Increased levels of potassium seen in blood test 
- Decreased appetite 
- Tremors 
- Feeling sick 
- Abnormal swelling, bleeding and/or inflammation of the gums 
- Indigestion 
- Hair loss 
- Excessive and/or abnormal hair growth on any part of the body </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects, you can help provide more information on the safety 
of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store lupkynis"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store lupkynis"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. 
Do not use this medicine after the expiry date which is stated on the carton and blister after  EXP . 
The expiry date refers to the last day of that month. 
Store in the original blister in order to protect from moisture. 
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Lupkynis contains 
- The active substance is voclosporin. Each soft capsule of Lupkynis contains 7.9 mg of 
voclosporin. 
- The other ingredients are: 
Capsule content: ethanol, vitamin E (E307) polyethylene glycol succinate (tocofersolan), 
polysorbate 40 and medium-chain triglycerides 
Capsule shell: gelatin, sorbitol, glycerin, purified water, titanium dioxide (E171), iron oxide red 
(E172), iron oxide yellow (E172) 
Processing aid: soya lecithin </p>
<p>What Lupkynis looks like and contents of the pack 
Lupkynis 7.9 mg pink/orange, soft capsules measuring approximately 13 mm   6 mm packed in 
blisters. Each blister contains 18 soft capsules. One carton contains 180 or 576 soft capsules. 
Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder 
Otsuka Pharmaceutical Netherlands B.V. 
Herikerbergweg 1101 CT Amsterdam 
Netherlands </p>
<p>Manufacturer 
Millmount Healthcare Limited 
Block-7, City North Business Campus, Stamullen, Co. Meath, K32 YD60, 
Ireland </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
Otsuka Pharmaceutical Netherlands B.V. 
T l/Tel: +31 (0) 20 85 46 Lietuva 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 <br />
Otsuka Pharmaceutical Netherlands B.V. 
Te : +31 (0) 20 85 46 Luxembourg/Luxemburg 
Otsuka Pharmaceutical Netherlands B.V. 
T l/Tel: +31 (0) 20 85 46  esk  republika 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Magyarorsz g 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Danmark 
Otsuka Pharma Scandinavia AB 
Tlf: +46 (0) 8 545 286 Malta 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Deutschland 
Otsuka Pharma GmbH 
Tel: +49 (0) 69 1700 Nederland 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Eesti 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Norge 
Otsuka Pharma Scandinavia AB 
Tlf: +46 (0) 8 545 286 <br />
Otsuka Pharmaceutical Netherlands B.V. 
Th : +31 (0) 20 85 46  sterreich 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Espa a 
Otsuka Pharmaceutical S.A 
Tel: +34 (0) 93 208 1Polska 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 France 
Otsuka Pharmaceutical France SAS 
T l: +33 (0) 1 47 08 00 Portugal 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Hrvatska 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Rom nia 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Ireland 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Slovenija 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46  sland 
Otsuka Pharma Scandinavia AB 
S mi: +46 (0) 8 545 286 Slovensk  republika 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Italia 
Otsuka Pharmaceutical Italy S.r.l. 
Tel: +39 (0) 2 0063 2Suomi/Finland 
Otsuka Pharma Scandinavia AB 
Puh/Tel: +46 (0) 8 545 286 <br />
Otsuka Pharmaceutical Netherlands B.V. 
Th : +31 (0) 20 85 46 Sverige 
Otsuka Pharma Scandinavia AB 
Tel: +46 (0) 8 545 286 Latvija 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 United Kingdom (Northern Ireland) 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 This leaflet was last revised in . </p>
<p>Other sources of information 
Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-41b3735a6e59fac8a0512a47fdc116bd
InstanceOf: CompositionUvEpi
Title: "Composition for lupkynis Package Leaflet"
Description:  "Composition for lupkynis Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp043229dc0e0f21b924ddb8c3894e484a)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - lupkynis"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse 
2. Det skal du vide, før du begynder at tage Lupkynis 
3. Sådan skal du tage Lupkynis 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What lupkynis is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What lupkynis is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Lupkynis indeholder det aktive stof voclosporin. Det anvendes til behandling af lupus nefritis 
(inflammation/betændelse i nyrerne forårsaget af lupus) hos voksne i alderen 18 år eller derover. </p>
<p>Det aktive stof i Lupkynis tilhører en gruppe lægemidler, der kaldes calcineurinhæmmere, og som kan 
anvendes til kontrol af kroppens immunforsvar (immunsvækkende stoffer). Ved lupus går kroppens 
eget immunforsvar ved en fejl til angreb på dele af kroppen, herunder nyrerne (lupus nefritis). 
Lægemidlet nedsætter immunsystemets respons og medfører derved en reduktion af 
inflammationen/betændelsen i nyrerne og en mindskning af symptomerne, herunder hævede ben, 
ankler eller fødder, forhøjet blodtryk og træthed, samt en bedring af nyrefunktionen. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take lupkynis"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take lupkynis"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Lupkynis 
- hvis du er allergisk over for voclosporin eller et af de øvrige indholdsstoffer i Lupkynis (angivet 
i punkt 6). 
- hvis du tager andre lægemidler som f.eks. ketoconazol-tabletter (til behandling af Cushings 
syndrom, når kroppen producerer for meget kortisol), itraconazol eller clarithromycin (til 
behandling af visse svampe- og bakterieinfektioner). </p>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen eller apotekspersonalet, før du tager Lupkynis, hvis noget af følgende gælder for dig:</p>
<ul>
<li>Hvis din nyresygdom forværres, skal din dosis af lægemidlet muligvis ændres. Lægen vil 
regelmæssigt kontrollere, hvor godt dine nyrer fungerer. </li>
<li>Hvis du har risikofaktorer for pure red cell aplasia (PRCA), der er en sjælden sygdom, hvor 
knoglemarven ikke danner tilstrækkeligt med røde blodlegemer. Sådanne risikofaktorer er 
tidligere infektion med parvovirus B19 eller andre tidligere behandlinger, der kan medføre 
PRCA. </li>
<li>Hvis du har eller udvikler forhøjet blodtryk. Lægen vil tjekke dit blodtryk hver 2. uge den første 
måned og derefter med regelmæssige mellemrum. Lægen kan give dig blodtrykssænkende 
medicin eller vurdere, at du skal holde op med at tage dette lægemiddel. </li>
<li>Dette lægemiddel kan øge risikoen for lidelser i nervesystemet, herunder hovedpine, skælven, 
synsændringer, krampeanfald, forvirring eller svaghed i et eller flere lemmer. Hvis du får et 
eller flere af disse nye symptomer eller oplever forværring af eksisterende symptomer, kan 
lægen vurdere, at du skal stoppe med at tage dette lægemiddel eller have en lavere dosis 
(se pkt. 4). </li>
<li>Hvis du planlægger at få en vaccination, eller hvis du har fået en vaccination inden for de 
seneste 30 dage. Dette lægemiddel kan påvirke responset på vaccination, idet vacciner, der 
indgives under behandling med dette lægemiddel, kan være mindre effektive. </li>
<li>Hvis du tidligere har haft pludselige og livstruende allergiske reaktioner (anafylaktiske 
reaktioner) over for soja eller jordnødder, må du ikke få dette lægemiddel. </li>
</ul>
<p>Dette lægemiddel kan øge kaliumniveauet i blodet, hvilket kan være alvorligt og kræve behandling. 
Lægen vil regelmæssigt kontrollere dit kaliumniveau under behandlingen. </p>
<p>Dette lægemiddel er ikke undersøgt hos patienter med alvorlige leverproblemer og anbefales derfor 
ikke til disse patienter. </p>
<p>Dette lægemiddel kan påvirke hjertets elektriske aktivitet (QT-forlængelse). Det kan give alvorlige 
hjerterytmeforstyrrelser. Tidlige symptomer er svimmelhed og besvimelse. </p>
<p>Sollys og UV-lys 
Dette lægemiddel øger risikoen for udvikling af visse typer kræft, navnlig hudkræft. Du skal undgå 
eller begrænse eksponering for sollys og UV-lys ved at gå med tilstrækkeligt beskyttende tøj og sørge 
for hyppig påføring af solcreme med høj beskyttelsesfaktor. </p>
<p>Infektioner 
Dette lægemiddel kan øge risikoen for at udvikle infektioner, herunder alvorlige eller dødelige 
infektioner. Kontakt lægen, hvis du får nogen tegn på infektion, f.eks. feber, kulderystelser eller ondt i 
halsen. Lægen vil vurdere, om du skal holde op med at tage lægemidlet (se pkt. 4). </p>
<p>Børn og unge 
Tag ikke dette lægemiddel, hvis du er under 18 år, da det ikke er undersøgt i denne aldersgruppe. </p>
<p>Ældre 
Dette lægemiddel anbefales ikke, hvis du er over 75 år, da det ikke er undersøgt i denne aldersgruppe. </p>
<p>Brug af anden medicin sammen med Lupkynis 
Sig det til lægen eller apotekspersonalet, hvis du tager, for nylig har taget eller planlægger at tage 
andre lægemidler. </p>
<p>Fortæl det navnlig til lægen, hvis du tager:</p>
<ul>
<li>medicin til behandling af svampeinfektioner, f.eks. itraconazol og fluconazol. </li>
<li>medicin til behandling af Cushings syndrom (når kroppen producerer for meget kortisol), f.eks. 
ketoconazol-tabletter. </li>
<li>medicin til behandling af forhøjet blodtryk eller hjerteproblemer, f.eks. digoxin, diltiazem og 
verapamil. </li>
<li>medicin til forebyggelse af blodpropper, f.eks. dabigatranetexilat. </li>
<li>medicin til behandling af epilepsi, f.eks. carbamazepin og phenobarbital. </li>
<li>naturlægemidler, der indeholder prikbladet perikum (til behandling af let depression). </li>
<li>medicin til lindring af symptomer ved sæsonbestemt høfeber, f.eks. fexofenadin. </li>
<li>antibiotiske lægemidler til behandling af bakterieinfektioner, f.eks. rifampicin, clarithromycin 
og erythromycin. </li>
<li>medicin mod forhøjet kolesterol, f.eks. simvastatin, atorvastatin, rosuvastatin og pravastatin. </li>
<li>medicin til behandling af hiv-infektioner, f.eks. det antiretrovirale lægemiddel efavirenz. </li>
</ul>
<p>Brug af Lupkynis sammen med mad og drikke 
Dette lægemiddel kan tages med eller uden mad. Du må ikke spise grapefrugt og drikke 
grapefrugtjuice under behandlingen med dette lægemiddel, da det kan påvirke lægemidlets virkemåde. </p>
<p>Graviditet, amning og frugtbarhed 
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge din læge til råds, før du tager dette lægemiddel. </p>
<p>Dette lægemiddel bør ikke anvendes under graviditet og hos fødedygtige kvinder, der ikke bruger 
prævention. </p>
<p>Sig det til lægen, hvis du ammer. Det vides ikke, om lægemidlet kan udskilles i modermælk og 
påvirke barnet. Lægen vil drøfte med dig, om du skal standse behandlingen med dette lægemiddel, 
mens du ammer, eller om du skal ophøre med at amme. </p>
<p>Der foreligger ingen data om dette lægemiddels indvirkning på forplantningsevnen hos mennesker. </p>
<p>Trafik- og arbejdssikkerhed 
Lupkynis forventes ikke at påvirke din evne til at føre motorkøretøj og betjene maskiner. </p>
<p>Lupkynis indeholder alkohol 
Dette lægemiddel indeholder 21,6 mg alkohol (ethanol) i hver kapsel. En dosis på 3 kapsler Lupkynis 
indeholder således 64,8 mg ethanol, hvilket svarer til under 2 ml øl eller 1 ml vin. Den lille mængde 
alkohol, der er i dette lægemiddel, vil ikke have nogen mærkbar effekt. </p>
<p>Lupkynis indeholder sorbitol 
Dette lægemiddel indeholder 28,7 mg sorbitol i hver kapsel. </p>
<p>Lupkynis kan indeholde sojalecitin<br />
Dette lægemiddel kan indeholde spor af sojalecitin. Hvis du har oplevet anafylaktiske reaktioner på 
soja eller jordnødder, må du ikke bruge dette lægemiddel. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take lupkynis"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take lupkynis"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens anvisning. Er du i tvivl, så spørg lægen eller 
apotekspersonalet. </p>
<p>Den anbefalede dosis Lupkynis er tre kapsler to gange dagligt (tages gennem munden). </p>
<p>Kapslerne skal sluges hele og kan tages med eller uden mad. </p>
<p>Tag de daglige doser på omtrent samme tidspunkt hver dag med mindst 8 timers mellemrum og meget 
gerne med 12 timers mellemrum (så tæt på som muligt, f.eks. kl. 8.00 om morgenen og kl. 20.00 om 
aftenen). </p>
<p>Dette lægemiddel bør tages i kombination med et andet immunsvækkende lægemiddel 
(mycophenolatmofetil). </p>
<p>Hvis du har taget for meget Lupkynis 
Hvis du er kommet til at tage for mange kapsler, skal du øjeblikkeligt kontakte lægen eller tage på 
skadestuen. Symptomer på overdosering kan omfatte hurtig hjerterytme og skælven (ukontrollerede 
rystelser i en eller flere dele af kroppen). </p>
<p>Hvis du har glemt at tage Lupkynis 
Hvis du glemmer en dosis, skal du tage den så hurtigt som muligt, hvis der ikke er gået mere end 
4 timer efter det planlagte tidspunkt for den glemte dosis. Hvis der er gået mere end 4 timer, siden du 
skulle have taget dosen, skal du springe den over og tage den næste planlagte dosis på det sædvanlige 
tidspunkt. Du må ikke tage en dobbeltdosis som erstatning for den glemte dosis. </p>
<p>Hvis du holder op med at tage Lupkynis 
Stop ikke behandlingen, medmindre lægen siger, du skal. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. 
Dette lægemiddel kan give følgende bivirkninger: </p>
<p>Alvorlige bivirkninger </p>
<p>Hvis du får en eller flere af disse bivirkninger, skal du kontakte lægen, som kan råde dig til at ophøre 
med at tage dette lægemiddel eller reducere dosen. </p>
<p>Meget almindelig (kan forekomme hos mere end 1 ud af 10 patienter) 
- Symptomer på infektion (f.eks. feber, ømhed i kroppen, træthed, hoste eller nysen, kvalme, 
opkastning eller diarré) </p>
<p>Almindelig (kan forekomme hos op til 1 ud af 10 patienter) 
- Nyopståede symptomer på nerve- eller hjernepåvirkning, f.eks. krampeanfald </p>
<p>Andre bivirkninger </p>
<p>Meget almindelig (kan forekomme hos mere end 1 ud af 10 patienter) 
- Infektion i de øvre luftveje 
- Nedsat antal røde blodlegemer (kan gøre huden bleg og forårsage svaghed eller åndenød 
(anæmi)) 
- Hovedpine 
- Forhøjet blodtryk 
- Hoste 
- Diarré 
- Mavesmerter 
- Ændret nyrefunktion, hvilket kan betyde nedsat mængde urin samt ny eller forværret hævelse i 
benene eller fødderne </p>
<p>Almindelig (kan forekomme hos op til 1 ud af 10 patienter) 
- Infektioner, der enten skyldes bakterier (f.eks. urinvejsinfektion) eller virus (f.eks. helvedesild) 
- Betændelse i mave-tarm-kanalen 
- Influenza 
- Forhøjet kalium i blodprøver 
- Nedsat appetit 
- Skælven 
- Kvalme 
- Unormal hævelse, blødning og/eller betændelse i tandkødet 
- Fordøjelsesbesvær 
- Hårtab 
- Kraftig og/eller unormal hårvækst et eller flere steder på kroppen </p>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge eller apotekspersonalet. Dette gælder også 
mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også 
indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store lupkynis"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store lupkynis"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. 
Brug ikke lægemidlet efter den udløbsdato, der står på æsken og blisterpakningen efter EXP. 
Udløbsdatoen er den sidste dag i den nævnte måned. 
Opbevares i den originale blisterpakning for at beskytte mod fugt. 
Spørg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke 
smide medicinrester i afløbet, toilettet eller skraldespanden.  </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Lupkynis indeholder:</p>
<ul>
<li>Aktivt stof: voclosporin Hver blød kapsel Lupkynis indeholder 7,9 mg voclosporin. </li>
<li>Øvrige indholdsstoffer: 
Kapselindhold: ethanol, E-vitamin (E307)-polyethylenglycolsuccinat (tocofersolan), polysorbat 
40 og mellemlange triglyceridkæder 
Kapselskal: gelatine, sorbitol, glycerin, renset vand, titandioxid (E171), rød jernoxid (E172), gul 
jernoxid (E172) 
Hjælpestof: sojalecitin </li>
</ul>
<p>Udseende og pakningsstørrelser 
Lupkynis 7,9 mg lyserøde/orange bløde kapsler på ca. 13 × 6 mm pakket i blisterkort. Hvert blisterkort 
indeholder 18 bløde kapsler. Én æske indeholder 180 eller 576 bløde kapsler. 
Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen 
Otsuka Pharmaceutical Netherlands B.V. 
Herikerbergweg 1101 CT Amsterdam 
Holland </p>
<p>Fremstiller 
Millmount Healthcare Limited 
Block-7, City North Business Campus, Stamullen, Co. Meath, K32 YD60, 
Irland </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
Otsuka Pharmaceutical Netherlands B.V. 
Tél/Tel: +31 (0) 20 85 46<br />
Lietuva 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46<br />
България 
Otsuka Pharmaceutical Netherlands B.V. 
Teл: +31 (0) 20 85 46<br />
Luxembourg/Luxemburg 
Otsuka Pharmaceutical Netherlands B.V. 
Tél/Tel: +31 (0) 20 85 46<br />
Česká republika 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46<br />
Magyarország 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46<br />
Danmark 
Otsuka Pharma Scandinavia AB 
Tlf: +46 (0) 8 545 286<br />
Malta 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46<br />
Deutschland 
Otsuka Pharma GmbH 
Tel: +49 (0) 69 1700<br />
Nederland 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46<br />
Eesti 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46<br />
Norge 
Otsuka Pharma Scandinavia AB 
Tlf: +46 (0) 8 545 286<br />
Ελλάδα 
Otsuka Pharmaceutical Netherlands B.V. 
Thλ: +31 (0) 20 85 46<br />
Österreich 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46<br />
España 
Otsuka Pharmaceutical S.A 
Tel: +34 (0) 93 208 1 
Polska 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46<br />
France 
Otsuka Pharmaceutical France SAS 
Tél: +33 (0) 1 47 08 00<br />
Portugal 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46<br />
Hrvatska 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46<br />
România 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46<br />
Ireland 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46<br />
Slovenija 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46<br />
Ísland 
Otsuka Pharma Scandinavia AB 
Sími: +46 (0) 8 545 286<br />
Slovenská republika 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46<br />
Italia 
Otsuka Pharmaceutical Italy S.r.l. 
Tel: +39 (0) 2 0063 2 
Suomi/Finland 
Otsuka Pharma Scandinavia AB 
Puh/Tel: +46 (0) 8 545 286<br />
Κύπρος 
Otsuka Pharmaceutical Netherlands B.V. 
Thλ: +31 (0) 20 85 46<br />
Sverige 
Otsuka Pharma Scandinavia AB 
Tel: +46 (0) 8 545 286<br />
Latvija 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46<br />
United Kingdom (Northern Ireland) 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46  </p>
<p>Denne indlægsseddel blev senest ændret </p>
<p>Andre informationskilder 
Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu. Der er også links til andre websteder om sjældne sygdomme 
og om, hvordan de behandles. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-41b3735a6e59fac8a0512a47fdc116bd
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for lupkynis Package Leaflet for language en"
Description: "ePI document Bundle for lupkynis Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-41b3735a6e59fac8a0512a47fdc116bd"
* entry[0].resource = composition-en-41b3735a6e59fac8a0512a47fdc116bd

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp41b3735a6e59fac8a0512a47fdc116bd"
* entry[=].resource = mp41b3735a6e59fac8a0512a47fdc116bd
                            
                    
Instance: bundlepackageleaflet-da-41b3735a6e59fac8a0512a47fdc116bd
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for lupkynis Package Leaflet for language da"
Description: "ePI document Bundle for lupkynis Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-41b3735a6e59fac8a0512a47fdc116bd"
* entry[0].resource = composition-da-41b3735a6e59fac8a0512a47fdc116bd

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp41b3735a6e59fac8a0512a47fdc116bd"
* entry[=].resource = mp41b3735a6e59fac8a0512a47fdc116bd
                            
                    



Instance: mp41b3735a6e59fac8a0512a47fdc116bd
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Lupkynis 7.9 mg soft capsules"
Description: "Lupkynis 7.9 mg soft capsules"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/22/1678/001 (180 soft capsules)"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Lupkynis 7.9 mg soft capsules"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 41b3735a6e59fac8a0512a47fdc116bdListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "lupkynis"

* status = #current
* mode = #working

* title = "List of all ePIs associated with lupkynis"

* subject = Reference(mp043229dc0e0f21b924ddb8c3894e484a)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#lupkynis "lupkynis"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-41b3735a6e59fac8a0512a47fdc116bd) // lupkynis en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-41b3735a6e59fac8a0512a47fdc116bd) // lupkynis da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-41b3735a6e59fac8a0512a47fdc116bd
InstanceOf: List

* insert 41b3735a6e59fac8a0512a47fdc116bdListRuleset
    